Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5126]

PLEIADES: Daratumumab combinations for multiple myeloma

Dr Ajai Chari - Mount Sinai, New York City, USA

PLEIADES: Daratumumab combinations for multiple myeloma ( Dr Ajai Chari - Mount Sinai, New York City, USA )

Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory...

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

$Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )$

Treatment options for high risk relapsed/refractory multiple myeloma

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

$Treatment options for high risk relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )$

BCMA: A new biomarker for multiple myeloma

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

BCMA: A new biomarker for multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )

ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory...

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

$ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )$

BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed...

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

$BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )$

Successful implementation of biosimilars through effective communication

Dr Pauline Leonard - The Whittington Hospital, London, UK

Successful implementation of biosimilars through effective communication ( Dr Pauline Leonard - The Whittington Hospital, London, UK )

Practical considerations for introducing biosimilars

Simon Cheesman - University College Hospital, London, UK

Practical considerations for introducing biosimilars ( Simon Cheesman - University College Hospital, London, UK )

How real-world data generation can assist biosimilar implementation

Simon Cheesman - University College Hospital, London, UK

How real-world data generation can assist biosimilar implementation ( Simon Cheesman - University College Hospital, London, UK )

Regulatory principles for biosimilar medicines

Prof Paul Declerck - KU Leuven, Leuven, Belgium

Regulatory principles for biosimilar medicines ( Prof Paul Declerck - KU Leuven, Leuven, Belgium )

Biologics utilisation and its efficiency through a hospital pharmacy...

Jose Feio - University of Coimbra, Coimbra, Portugal

Biologics utilisation and its efficiency through a hospital pharmacy centralised management system ( Jose Feio - University of Coimbra, Coimbra, Portugal )

The science of biosimilarity: Immunogenicity

Prof João Gonçalves - University of Lisbon, Lisbon, Portugal

The science of biosimilarity: Immunogenicity ( Prof João Gonçalves - University of Lisbon, Lisbon, Portugal )

More from ecancer